BioNTech, Pfizer to develop single-dose jab for COVID

Thursday, 03. November 2022 13:02

Pfizer and BioNTech began a study of a single-dose vaccine candidate for influenza and COVID-19, BioNTech said Thursday.

The study will combine Pfizer's quadrivalent modRNA-based influenza vaccine and Pfizer and BioNTech's authorized Omicron-adapted bivalent COVID-19 BNT162b2. The study advanced today to a Phase 1 trial, the release said.

"By combining both indications in one vaccine approach, we aim to provide individuals with an efficient way to receive immunization against two severe respiratory diseases with evolving viruses that require vaccine adaptation," said Prof. Ugur Sahin, M.D., CEO and Co-founder of BioNTech.

Related Links: Pfizer Inc.BioNTech SE
Author:
Baha Breaking News (BBN) / JG